Dr Daniel Drucker is a clinical researcher involved in the development of treatments for diabetes, obesity and intestinal disorders at the University of Toronto Lunenfeld-Tanenbaum Research Institute. He also holds the Canada Research Chair in Regulatory Peptides and the Banting and best Diabetes Centre-Novo Nordisk chair in Incretin biology. He will be giving his Society Transatlantic Medal Lecture during SfE BES Online 2020. In this interview he tells us a little about his research and career.
Tell us about your research and lab in Toronto
I have a medium-sized lab of 8 people, where we use molecular biology and mouse physiology to study peptide hormone action. Whenever possible, we also try and extend our findings to humans, using available tissues, or occasionally, by carrying out small clinical trials. The lab has carried out basic research leading to two new treatments for type 2 diabetes and one new therapy for short bowel syndrome.
Tell us about your career path
I was very fortunate to learn molecular biology under the tutelage of Joel Habener in Boston. I returned to Toronto and was guided to adopt transgenic and knockout mice, which proved to be wise counsel. I think I am most proud of my dozens of trainees and their success. We also take pride in being extremely careful-that sounds trite, but we are generally not as concerned about being first, rather, we are very focused on making sure the data and observations are as correct as they can be. This article includes some of my career highlights in discovery, characterization, and clinical development of glucagon-like peptides.
What inspired you to choose endocrinology as a career?
I had a great role model, Gerard Burrow, who was an enthusiastic mentor, and head of endocrinology. At the same time, endocrinology was appealing since one could understand many of the disorders, and there were multiple treatments available to correct endocrine deficiencies or hormone excess states.
What do you enjoy most about your work?
I like the ability to ask questions, carry out experiments, and then scrutinise the answers. Watching trainees mature as scientists is also very enjoyable. Finally, having the good fortune to see basic science translated into new medicines is a privilege and extremely rewarding.
What are you presenting during your Medal Lecture at SfE BES Online 2020?
My presentation, ‘Incretins and Cardiometabolic Disease-An Inflammatory Perspective’ will examine how inflammation underlies many of the common endocrine disorders in metabolism, from type 2 diabetes to heart disease, to the complications of obesity and fatty liver. Gut peptides, exemplified by GLP-1, attenuate inflammation in many organ systems. I will describe how GLP-1 might work, and highlight many unanswered questions, surrounding the anti-inflammatory actions of GLP-1.
What do you think about the move to virtual meetings?
Virtual meetings allow for a broader and larger global audience, and enable us to continue to share data and concepts. I suspect that many of us still miss the social and personal interactions, and we will be keen to return to many of the in person meetings once this is feasible.
What do you think are the biggest challenges in your field?
What do you think will be the next major breakthrough in your field?
I am hopeful that stem cell therapy will solve many challenges and mature to allow for true beta cell replacement therapy for people with type 1 diabetes.
Any words of advice for aspiring endocrinologists?
Have fun, find a good environment, choose mentors that are supportive, and don’t take yourself too seriously!
You can hear Dr Daniel Drucker’s Medal Lecture “Incretins and Cardiometabolic Disease-An Inflammatory Perspective” on Wednesday 18 November at 15:55 GMT.
If you haven’t already, register for SfE BES Online now!